Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend Industry Events in March
01 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
28 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Dyadic מקדמת שיתוף פעולה עם המכון הביולוגי הישראלי (IIBR) להתמקדות באיומים ביולוגיים ופתרונות למחלות מתפתחות
23 févr. 2024 02h00 HE
|
Dyadic International, Inc.
יופיטר, פלורידה ונס-ציונה, ישראל, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc ("דיאדיק" או "החברה") (נאסד"ק: DYAI), חברת ביוטכנולוגיה גלובלית המתמחה בפלטפורמות מיקרוביאליות מתקדמות...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
23 févr. 2024 02h00 HE
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
21 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
13 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences®...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
01 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...